valu usd unless otherwis note
titan dont mean movi weak
outlook sink share
view report ep miss inventori write-down
cordi busi relat tax expens revis guidanc
downward compani also outlin sever headwind make us
pessimist growth
report weak result commentari report
ep vs estim street
miss larg due cardin pay adjust tax rate vs
estim due inventori write-down relat loss
cordi busi neg effect cah geograph mix
earn despit ep miss record oper profit
modestli beat estim revenu
in-lin estim compani also cut ep guid fy
reflect weak cordi
neg effect tax rate share sank almost
challeng manag cite reduc guidanc weak
cordi caus reduct ep quarter due
effect weak geograph distribut cah profit
poor perform larg part due larg inventori write-
result better insight proper inventori level
segment manag state cordi issu oper
channel check lead us believ may end-market
competit issu well manag expect return profit
growth cordi though cautiou compani
evalu consign inventori manag also state
expect fy sell-sid gener deflat mid-high singl digit
rather mid-singl digit reignit concern headwind across
drug wholesal segment furthermor manag cite loss
pharmerica higher-than-norm number custom repric
arrang weigh expect
reduc estim adjust estim
account result headwind face cardin lower
ep y/i sever gener
price deflat impact weak cordi higher expect
tax rate lower ep account
headwind along manag commentari custom
maintain sector perform lower price target maintain sector
perform rate lower price target lower
multipl one turn appli reduc ep estim
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
cardin health one three larg drug wholesal
unit state believ share like
multipl range-bound investor get visibl
gener drug price bottom oper
earn growth resum compani
pressur last month gener drug price
deflat increas wholesal competit higher-margin
independ custom slowdown brand drug price
increas weigh result expect
backdrop improv next twelv month end
believ investor expect estim
compani core drug distribut segment bottom
could continu disappoint
estim cardin gener
profit core us drug distribut busi sale
gener drug past two year cardin seen
price gener drug deflat high singl digit mid-teen
percentag rate profit dollar contribut fall
slightli lower rate cardin grow profit gener
drug need volum growth new introduct off-set
impact drug price deflat believ
possibl gener deflat continu high singl digit
pace higher thu current environ persist
upsid risk rate includ stabil drug
price environ could caus earn estim
stabil like drive multipl expans close
outperform expect drive posit earn
gener market potenti client loss
wholesal sell side price compress
larger pharmaci custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
slight discount year averag forward trade multipl
share
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep upsid scenario
ep better ep growth could driven
success medic devic strategi increas volum across
brand gener drug de-lever balanc sheet
level gener price deflat forward
multipl repres high end normal trade
rang drug wholes space multipl
like get neg share
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower expect ep could
driven hiccup implement medic devic
strategi wors expect price environ lower
expect brand gener volum forward
multipl like get posit share
result varianc tabl act commentsrevenuepharmacet despit continu gener price deflationmed driven cordistot profit oper oper adj medic adj total adj op incom expense- interest loss debt extinguishment- profit incom cont profit incom adjust tax effect cordisadj net ep dilut cont acq-rel discontinu op adjust ep average number share healthbp profitadj oper profit healthcar technolog distribut
price target share equal ep estim use
multipl reflect slight discount year averag forward trade multipl
share reflect challeng medic segment price target support
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
cah medic surgic busi could also outperform expect drive posit
earn surpris downsid risk includ acceler drug price deterior
gener market potenti client loss wholesal sell side
price compress larger pharmaci custom gpo
healthcar servic product compani offer solut health
system pharmaci healthcar provid compani oper
medic segment busi distributor
brand gener drug specialti drug over-the-counter healthcar product
segment also provid specialti pharmaci servic china joint ventur
call red oak sourc sourc gener pharmaceut
medic busi distributor nation brand medic surgic
laboratori product healthcar provid patient home segment addit
provid profession servic healthcar provid
good sold
revenu
impair charg net
litig credit net
revenu
adj profit tax
profit tax
weight average number share
